PubMed · 15942287
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Charles W Callahan. Bronchiectasis: abated or aborted?. https://doi.org/10.1159/000085359
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
We retrospectively analysed 23 children originating from Campania--Southern Italy--with recurrent pneumonia and chest high-resolution computed tomography (HRCT) proven bronchiectasis. In six patients (26%) who had not undergone measles or pertussis vaccination, recurrent pneumonia started after an episode of lower respiratory tract infection complicating pertussis (n=2) or measles (n=4), contracted at a mean age of 3.6 years. Thirty-three percent (2/6) and 67% (4/6) of the patients had bilateral or monolobar disease, respectively, while in two subjects (33%) bronchiectasis were found in all lobes. These findings indicate an increased risk of developing bronchiectasis after measles or pertussis.
Explore the source record for details and available documents.
BACKGROUND: Mucus retention in the lungs is a prominent feature of bronchiectasis. The stagnant mucus becomes chronically colonised with bacteria, which elicit a host neutrophilic response. This fails to eliminate the bacteria, and the large concentration of host-derived protease may contribute to the airway damage. The sensation of retained mucus is itself a cause of suffering, and the failure to maintain airway sterility probably contributes to the frequent respiratory infections experienced by many patients. Hypertonic saline inhalation is known to accelerate tracheobronchial clearance in many conditions, probably by inducing a liquid flux into the airway surface, which alters mucus rheology in a way favourable to mucociliary clearance. Inhaled dry powder mannitol has a similar effect. Such agents are an attractive approach to the problem of mucostasis, and deserve further clinical evaluation. OBJECTIVES: To determine whether inhaled hyperosmolar substances are efficacious in the treatment of bronchiectasis SEARCH STRATEGY: The Cochrane Airways Group Specialised Register was searched, and leaders in the field were contacted. Searches were current as of October 2005. Search updates will be run annually. SELECTION CRITERIA: Any trial using hyperosmolar inhalation in patients with bronchiectasis not caused by cystic fibrosis. DATA COLLECTION AND ANALYSIS: Two reviewers assessed studies for suitability. MAIN RESULTS: Two small studies met the inclusion criteria of the review (28 participants). One study reported tracheobronchial clearance of a particulate radio aerosol after inhalation of dry mannitol on a single occasion, with appropriate control. Airway clearance doubled in the central and intermediate regions of the lung, but not in the peripheral region, after mannitol administration. No side effects were observed, but two patients were premedicated with nedocromil to prevent bronchospasm. Findings from one further trial indicated that one domain of a sensitive health status instrument showed a favourable response to mannitol. AUTHORS' CONCLUSIONS: Dry powder mannitol has been shown to improve tracheobronchial clearance in bronchiectasis, as well as cystic fibrosis, asthmatics, and normal subjects. Hypertonic saline has not been specifically tested in bronchiectasis, but improves clearance in these other conditions and in chronic bronchitis. The measurement of health status in one of the studies should be repeated in future longer term randomised controlled studies of mannitol and hypertonic saline. Consideration should also be given to exacerbations and symptom scores, as well as drug-related adverse events.